Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 7/2013

01-07-2013 | Brief report

Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors

Authors: Christina B. Rasmussen, Mette T. Faber, Allan Jensen, Estrid Høgdall, Claus Høgdall, Jan Blaakær, Susanne K. Kjaer

Published in: Cancer Causes & Control | Issue 7/2013

Login to get access

Abstract

Purpose

The aim of the study was to examine the potential association between a history of pelvic inflammatory disease (PID) and risk of epithelial ovarian cancer or ovarian borderline tumors.

Methods

In a population-based case–control study in Denmark, we included 554 women with invasive ovarian cancer, 202 with ovarian borderline tumors, and 1,564 controls aged 35–79 years. The analyses were performed in multiple logistic regression models.

Results

We found a significantly increased risk of ovarian borderline tumors among women with a history of PID (OR = 1.50; 95 % CI 1.08–2.08) but no apparent association between PID and risk of invasive ovarian cancer (OR = 0.83; 95 % CI 0.65–1.05). We found no effect of age at time of first PID or time since first PID on the risk for either condition.

Conclusion

Our results suggest that a history of PID is associated with an increased risk of ovarian borderline tumors, which may support the hypothesis that inflammation is an etiological factor. The lack of an association between previous PID and invasive ovarian cancer may indicate an etiological difference between ovarian borderline tumors and invasive ovarian cancer. However, an important limitation of the study is the use of self-reported PID.
Literature
1.
2.
Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717–721PubMed
3.
Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467PubMedCrossRef
4.
Shan W, Liu J (2009) Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle 8:3107–3111PubMedCrossRef
5.
Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM (2008) Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 98:1781–1783PubMedCrossRef
6.
Baandrup L, Faber MT, Christensen J, Jensen A, Andersen KK, Friis S et al (2013) Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand 92:245–255PubMedCrossRef
7.
Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ et al (2011) Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 12:900–904PubMedCrossRef
8.
Lareau SM, Beigi RH (2008) Pelvic inflammatory disease and tubo-ovarian abscess. Infect Dis Clin North Am 22:693–708, vii
9.
Kurman RJ, Vang R, Junge J, Hannibal CG, Kjaer SK, Shih I (2011) Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 35:1605–1614PubMedCrossRef
10.
Salvador S, Gilks B, Kobel M, Huntsman D, Rosen B, Miller D (2009) The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 19:58–64PubMedCrossRef
11.
Seidman JD, Sherman ME, Bell KA, Katabuchi H, O’Leary TJ, Kurman RJ (2002) Salpingitis, salpingoliths, and serous tumors of the ovaries: is there a connection? Int J Gynecol Pathol 21:101–107PubMedCrossRef
12.
Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE et al (2000) Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11:111–117PubMedCrossRef
13.
Parazzini F, La Vecchia C, Negri E, Moroni S, dal Pino D, Fedele L (1996) Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 5:667–669PubMed
14.
Risch HA, Howe GR (1995) Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 4:447–451PubMed
15.
Shu XO, Brinton LA, Gao YT, Yuan JM (1989) Population-based case–control study of ovarian cancer in Shanghai. Cancer Res 49:3670–3674PubMed
16.
Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122:170–176PubMedCrossRef
17.
Huusom LD, Frederiksen K, Hogdall EV, Glud E, Christensen L, Hogdall CK et al (2006) Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case–control study. Cancer Causes Control 17:821–829PubMedCrossRef
18.
Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J et al (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 16:1160–1166PubMedCrossRef
19.
Crispens MA (2003) Borderline ovarian tumours: a review of the recent literature. Curr Opin Obstet Gynecol 15:39–43PubMedCrossRef
20.
Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM et al (2001) Risk factors for epithelial borderline ovarian tumors: results of a Swedish case–control study. Gynecol Oncol 83:575–585PubMedCrossRef
21.
Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF et al (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29:218–224PubMedCrossRef
22.
Aral SO, Mosher WD, Cates W Jr (1985) Self-reported pelvic inflammatory disease in the US: a common occurrence. Am J Public Health 75:1216–1218PubMedCrossRef
Metadata
Title
Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors
Authors
Christina B. Rasmussen
Mette T. Faber
Allan Jensen
Estrid Høgdall
Claus Høgdall
Jan Blaakær
Susanne K. Kjaer
Publication date
01-07-2013
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 7/2013
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-013-0216-y

Other articles of this Issue 7/2013

Cancer Causes & Control 7/2013 Go to the issue

Original paper

Periodontal disease and mouthwash use are risk factors for head and neck squamous cell carcinoma

Original paper

Intake of whole grains from different cereal and food sources and incidence of colorectal cancer in the Scandinavian HELGA cohort

Original paper

Exposure to pesticides and the risk of childhood brain tumors

Original paper

Reproductive factors and risk of lung cancer in female textile workers in Shanghai, China

Original paper

Anthropometric, behavioral, and female reproductive factors and risk of multiple myeloma: a pooled analysis

Original paper

Impact of hormone replacement therapy use on mammographic screening outcomes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits